Literature DB >> 23323154

A systemic complete response of metastatic melanoma to local radiation and immunotherapy.

Susan M Hiniker1, Daniel S Chen, Sunil Reddy, Daniel T Chang, Jennifer C Jones, Joseph A Mollick, Susan M Swetter, Susan J Knox.   

Abstract

BACKGROUND: Melanoma is a relatively immunogenic tumor, in which infiltration of melanoma cells by T lymphocytes is associated with a better clinical prognosis. We hypothesized that radiation-induced cell death may provide additional stimulation of an anti-tumor immune response in the setting of anti-CTLA-4 treatment.
METHODS: In a pilot melanoma patient, we prospectively tested this hypothesis. We treated the patient with two cycles of ipilimumab, followed by stereotactic ablative radiotherapy to two of seven hepatic metastases, and two additional cycles of ipilimumab.
RESULTS: Subsequent positron emission tomography-computed tomography scan indicated that all metastases, including unirradiated liver lesions and an unirradiated axillary lesion, had completely resolved, consistent with a complete response by RECIST.
CONCLUSION: The use of radiotherapy in combination with targeted immunotherapy as a noninvasive in vivo tumor vaccine strategy appears to be a promising method of enhancing the induction of systemic immune responses and anti-tumor effect.

Entities:  

Year:  2012        PMID: 23323154      PMCID: PMC3542835          DOI: 10.1593/tlo.12280

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  13 in total

1.  Anti-CTL-associated antigen 4: are regulatory T cells a target?

Authors:  Emmanuel M Gabriel; Edmund C Lattime
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

2.  Concomitant immunity to pulmonary metastases of a murine fibrosarcoma: influence of removal of primary tumor by radiation or surgery, of active specific immunization and treatment with Corynebacterium granulosum.

Authors:  L Milas; N Hunter; H R Withers
Journal:  Int J Radiat Oncol Biol Phys       Date:  1976 Nov-Dec       Impact factor: 7.038

3.  Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo.

Authors:  M F Krummel; T J Sullivan; J P Allison
Journal:  Int Immunol       Date:  1996-04       Impact factor: 4.823

4.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

5.  CTLA-4 can function as a negative regulator of T cell activation.

Authors:  T L Walunas; D J Lenschow; C Y Bakker; P S Linsley; G J Freeman; J M Green; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

6.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

Authors:  Sandra Demaria; Noriko Kawashima; Anne Marie Yang; Mary Louise Devitt; James S Babb; James P Allison; Silvia C Formenti
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

7.  Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.

Authors:  Steven K Seung; Brendan D Curti; Marka Crittenden; Edwin Walker; Todd Coffey; Janet C Siebert; William Miller; Roxanne Payne; Lyn Glenn; Alexandru Bageac; Walter J Urba
Journal:  Sci Transl Med       Date:  2012-06-06       Impact factor: 17.956

8.  Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.

Authors:  M Zahidunnabi Dewan; Ashley E Galloway; Noriko Kawashima; J Keith Dewyngaert; James S Babb; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

9.  Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells.

Authors:  Mengde Cao; Roniel Cabrera; Yiling Xu; Chen Liu; David Nelson
Journal:  Cell Biol Int       Date:  2009-03-04       Impact factor: 3.612

10.  Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.

Authors:  James C Yang; Marybeth Hughes; Udai Kammula; Richard Royal; Richard M Sherry; Suzanne L Topalian; Kimberly B Suri; Catherine Levy; Tamika Allen; Sharon Mavroukakis; Israel Lowy; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2007 Nov-Dec       Impact factor: 4.456

View more
  92 in total

Review 1.  The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant.

Authors:  Kobe Reynders; Tim Illidge; Shankar Siva; Joe Y Chang; Dirk De Ruysscher
Journal:  Cancer Treat Rev       Date:  2015-03-28       Impact factor: 12.111

Review 2.  Strategies for combining immunotherapy with radiation for anticancer therapy.

Authors:  Steven N Seyedin; Jonathan E Schoenhals; Dean A Lee; Maria A Cortez; Xiaohong Wang; Sharareh Niknam; Chad Tang; David S Hong; Aung Naing; Padmanee Sharma; James P Allison; Joe Y Chang; Daniel R Gomez; John V Heymach; Ritsuko U Komaki; Laurence J Cooper; James W Welsh
Journal:  Immunotherapy       Date:  2015-08-27       Impact factor: 4.196

3.  Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.

Authors:  Emily Z Keung; Jen-Wei Tsai; Ali M Ali; Janice N Cormier; Andrew J Bishop; B Ashleigh Guadagnolo; Keila E Torres; Neeta Somaiah; Kelly K Hunt; Jennifer A Wargo; Alexander J Lazar; Wei-Lien Wang; Christina L Roland
Journal:  Oncoimmunology       Date:  2017-10-31       Impact factor: 8.110

Review 4.  Immunological interactions in radiotherapy-opening a new window of opportunity.

Authors:  Tapesh Bhattacharyya; Kiran Purushothaman; Sanudev Sadanandan Vadakke Puthiyottil; Atanu Bhattacharjee; Geetha Muttah
Journal:  Ann Transl Med       Date:  2016-02

5.  Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

Authors:  Patrick A Ott; Omid Hamid; Anna C Pavlick; Harriet Kluger; Kevin B Kim; Peter D Boasberg; Ronit Simantov; Elizabeth Crowley; Jennifer A Green; Thomas Hawthorne; Thomas A Davis; Mario Sznol; Patrick Hwu
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

6.  The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications.

Authors:  Michael Spiotto; Yang-Xin Fu; Ralph R Weichselbaum
Journal:  Sci Immunol       Date:  2016-09-30

7.  Harnessing the Immunomodulatory Effects of Radiation in Urinary Bladder Cancer.

Authors:  Waseem Abbas; Vineeta Goel; Arun Verma; Vineet G Gupta; Ranga R Rao
Journal:  Cureus       Date:  2019-02-20

8.  TLR4-mediated immunomodulatory properties of the bacterial metalloprotease arazyme in preclinical tumor models.

Authors:  Felipe V Pereira; Amanda C L Melo; Filipe M de Melo; Diego Mourão-Sá; Priscila Silva; Rodrigo Berzaghi; Carolina C A Herbozo; Jordana Coelho-Dos-Reis; Jorge A Scutti; Clarice S T Origassa; Rosana M Pereira; Luis Juliano; Maria Aparecida Juliano; Adriana K Carmona; Niels O S Câmara; Moriya Tsuji; Luiz R Travassos; Elaine G Rodrigues
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

Review 9.  Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

Authors:  Michael B Bernstein; Sunil Krishnan; James W Hodge; Joe Y Chang
Journal:  Nat Rev Clin Oncol       Date:  2016-03-08       Impact factor: 66.675

Review 10.  Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era.

Authors:  Everett J Moding; Yvonne M Mowery; David G Kirsch
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.